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Reactive oxygen species (ROS) generation is critical in the regulation of platelets, 
which has important implications in the modulation of haemostasis and thrombosis. 
Nonetheless, despite several assays have been described and successfully utilised 
in the past, the analysis of ROS generation in human platelets remains challenging.   
Here we show that dihydroethidium (DHE) allows the characterisation of redox 
responses upon platelet activation by physiological and pathological stimuli. In 
particular, the flow cytometry assay that we describe here allowed us to confirm that 
thrombin, collagen-related peptide (CRP) and arachidonic acid but not adenosine 
diphosphate (ADP) stimulate superoxide anion formation in a concentration-
dependent manner. 0.1unit/ml thrombin, 3 µg/ml CRP and 30 µM arachidonic acid 
are commonly used to stimulate platelets in vitro and here were shown to stimulate a 
significant increase in superoxide anion formation. The ROS scavenger N-
acetylcysteine (NAC) abolished superoxide anion generation in response to all 
tested stimuli, but the pan-NADPH oxidase (NOX) inhibitor VAS2870 only inhibited 
superoxide anion formation in response to thrombin and CRP. The involvement of 
NOXs in thrombin and CRP-dependent responses was confirmed by the inhibition of 
platelet aggregation induced by these stimuli by VAS2870, while platelet aggregation 
in response to arachidonic acid was insensitive to this inhibitor.  
The pathological platelet stimulus amyloid β (Aβ) 1-42 peptide also stimulated 
superoxide anion formation in a concentration-dependent manner. Aβ peptide 
stimulated superoxide anion formation in a NOX-dependent manner, as proved by 
the use of VAS2870. Aβ 1-42 peptide displayed only moderate activity as an 
aggregation stimulus, but was able to significantly potentiate platelet aggregation in 
response to submaximal agonists concentrations, such as 0.03 unit/ml thrombin and 
10 µM arachidonic acid. The inhibition of NOXs by 10 µM VAS2870 abolished Aβ-
dependent potentiation of platelet aggregation in response to 10 µM arachidonic 
acid, suggesting that the pro-thrombotic activity of Aβ peptides depends on NOX 
activity. Similar experiments could not be performed with thrombin or collagen, as 
NOXs are required for the signalling induced by these stimuli. These finding shed 
some new light on the pro-thrombotic activity of Aβ peptides. 
In summary, here we describe a novel and reliable assay for the detection of 
superoxide anion in human platelets. This is particularly important for the 
investigation of the pathophysiological role of redox stress in platelets, a field of 
research of increasing importance, but hindered by the absence of a reliable and 








The generation of superoxide anion by platelets was described over 40 years ago 
[1]. In recent years, ROS have been described as critical players in platelet activation 
both in the healthy body and in disease [2, 3]. A role for ROS and especially 
superoxide anion in platelet hyperactivation in pathological conditions such as 
ischemia and hypercholesterolemia has become apparent [4, 5]. Interestingly, 
scavenging of ROS or inhibition of the enzymatic sources of these highly reactive 
species has been shown to inhibit platelet activation, which is suggested to underlie 
the antithrombotic activity of antioxidants [6, 7]. Amongst ROS-generating enzymes, 
NADPH oxidases (NOXs) play a key role in platelet regulation and haemostasis 
modulation [8, 9].   
Several molecular mechanisms have been described that underly ROS-dependent 
regulation of platelet activation. These include the increase in ADP release and 
bioavailability [9], the direct modulation of integrin αIIbβ3 [10], the modulation of 
integrin αIIbβ3 via inhibition of protein phosphatases [11], the reduction of nitric oxide 
levels by formation peroxynitrite [11, 12], the modulation of GPVI and its signalling 
[13], or the modulation of protein kinase C (PKC) [14]. How these molecular 
pathways affect different functional responses, downstream of which agonists they 
are activated and how they interact with each other is currently under investigation.  
Recent studies confirmed the importance of NOXs in the activation of platelets, 
although there is a discrepancy regarding which NOX enzymes are responsible for 
platelet activation in response to different stimuli. Human and mouse platelets 
express both NOX1 and NOXs [15]. ROS generated by NOX1 and NOX2 promote 
platelet activation via the Syk/phospholipase Cγ2/calcium signaling pathway [16]. In 
contrast with the above study, the work by Walsh and colleagues [17] suggested that 
NOX2 has no relevant role in response to collagen or collagen-related peptide 
(CRP), with NOX1 playing the main activating role in the signalling of the collagen-
specific GPVI receptor. NOX2 only appeared critical for the stabilization of the 
thrombus [17]. Despite the limitation of relying on a pharmacological inhibitor partially 
selective for NOX1, the study by Vara and colleagues [15] is in agreement with that 
of Walsh and colleagues, with NOX1 playing a key activating role in the signalling of 
GPVI. A recent study by Magwenzi and colleagues [18] described a critical role for 
NOX2 in the hyperactivity of platelets induced by oxidized low-density lipoprotein 
(LDL), which is typical of dyslipidemic disorders (e.g. hypercholesterolemia). 
Oxidised LDL inhibits cGMP-signaling through a mechanism that requires NOX2 and 
intracellular ROS, which leads to platelet hyperactivity. 
Despite the centrality of redox homeostasis in platelet regulation and the growing 
importance of ROS detection in haemostasis and thrombosis research, there is an 
alarming paucity of reliable cell assays for the detection of ROS in platelets. Assays 
with 2’,7’–dichlorofluorescein diacetate (DCFDA) are still largely used in the platelet 
field, despite the relevant limitations of this probe due to the generation of artefacts 
and its interaction with pharmacological tools often used for cell signalling studies 
[19, 20]. Dihydroethidium (DHE) has been consistently suggested as a safer 
alternative to DCFDA [20]. The detection of oxidation products of DHE by liquid 
chromatography mass spectrometry (LC-MS) is the most reliable approach and it 
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has been successfully applied to platelets [18]. Unfortunately, the detection of DHE 
oxidation by LC-MS is extremely laborious and requires equipment and skills usually 
absent in haemostasis and thrombosis laboratories. Here, we propose and validate 
an alternative fluorescence probe-based technique for the detection of superoxide 
anion in platelets based on the intracellular detection of 2-hydroxy-ethidium (2OH-
Et+), the product of DHE oxidation by superoxide anions. Using this technique, we 
revealed that the pro-thrombotic activity of amyloid peptide β [21-23] is accompanied 





Human blood was drawn from healthy volunteers by median cubital vein 
venepuncture under local ethics committee approval. Sodium citrate was used as 
anti-coagulant (0.5% w/v for platelet isolation - 0.1% w/v for whole blood 
experiments). Platelet suspensions were obtained as previously described [24]. 
Briefly, platelet-rich plasma (PRP) was separated from whole blood by centrifugation 
(200 x g, 15 min), and platelets were separated from PRP by a second centrifugation 
step (400 x g, 10 min), in the presence of prostaglandin E1 (40 ng/ml) and 
indomethacin (10 µM). Platelets were then resuspended in a modified Tyrode’s-
HEPES buffer (145 mM NaCl, 2.9 mM KCl, 10 mM HEPES, 1 mM MgCl2, 5 mM 
glucose, pH 7.3) at a density of 2 x 108 cells/ml. 
 
DHE-based detection of intracellular ROS by flow cytometry 
Platelet suspensions obtained as described above were rested for 30 minutes at 
37°C before incubation with 5 µM DHE for 15 minutes. Platelets were then 
stimulated with the physiological stimuli thrombin (0.01-1.0 unit/ml), CRP (0.1-10 
µg/ml), ADP (1-100 µM) or arachidonic acid (1-100 µM) for 15 minutes or with Aβ 
peptides (1-100 µM). Where indicated, a ROS scavenger (i.e. NAC) or an inhibitor 
(i.e. VAS2870 or indomethacin) was co-incubated with stimuli. At the end of the 
incubation time, platelet suspensions were diluted 1:10 in cold modified Tyrode’s-
HEPES buffer. Within 30 minutes from preparation, samples were then analysed 
using a FACSAria III flow cytometer with 85 µm nozzle at low flow rate. Gate 
selection (shown in Figure 3A) was performed using logarithmic side and forward 
scattering with the gain set at 40 and 220 mV, respectively. Fluorescence excitation 
was obtained with a violet laser at 405 nm and emission was collected at 580 nm 
with a LP600 filter. Baseline for unstimulated samples was set at 200 relative 
fluorescence units. The protocol is summarised schematically in Figure 1B. 
 
DHE-based detection of intracellular ROS by confocal microscopy 
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Glass coverslips were coated with 0.1 mg/ml fibrillar collagen I from equine tendons 
(Horm collagen). Platelets were diluted to a density of 4 x 107/ml and treated with 10 
µM dihydroethidium (DHE). After 1 minute of incubation, platelets were dispensed 
over the coverslip in a live cell-imaging chamber. Where indicated, ROS scavenger 
N-acetylcysteine (NAC, 1 mM) or NOX inhibitor VAS2870 (10 µM) were added to the 
live cell chamber. Oxidation-dependent probe conversion and fluorescence 
generation were monitored by confocal imaging for a period of 10 min (405/580 nm 
ex/em). Images were collected every 10 sec using a Zeiss 510 LSM confocal 
microscope equipped with a 40x oil immersion lens and single cell fluorescence was 
quantified using Zeiss LSM Examiner software (Zeiss, Jena, Germany). Single 
platelet fluorescence values were utilized to construct response curves (mean ± 
SEM). 
 
Platelet aggregation assay by suspension turbidimetry 
Human platelet suspensions at physiological density (2 x 108/ml) were stimulated 
with thrombin (0.01-1 unit/ml), CRP (0.1-10 µg/ml), ADP (1-100 µM), arachidonic 
acid (1-100 µM) or Aβ peptides (20 µM, with scrambled Aβ peptide 1-42 as a 
control). The aggregation experiments were performed for 8-10 min, with agonist 
addition at time 1 min. Where indicated, platelets where preincubated with a ROS 
scavenger (i.e. 3 mM NAC), an inhibitor (i.e. 10 µM VAS2870 or 10 µM 
indomethacin) or Aβ peptides (5-20 µM, with scrambled Aβ peptide 1-42 as a 
control). Aggregation was measured by turbidimetry at 37°C using a 490D 
aggregometer (Chrono-Log Corporation, Havertown, PA), as previously described 
[15]. 
 
Amyloid peptides and fibril formation 
Amyloid peptides were synthesised by Life Protein (New Jersey, US). The 
sequences of the peptides are the following: 
Aβ1-40: DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV (4.3 kDa)  
Aβ1-42: DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA (4.5 kDa) 
Scrambled Aβ1-42: DEFAKNIGHHDGVAVHMYKGRQVEFIGSIALVFEDVGSAGLV 
(4.5 kDa) 
Peptide fibrillation was obtained by resuspension in phosphate buffer saline (PBS, 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.3) and 
incubation for 24 h at 37°C. Thioflavin T was used to monitor fibril formation, as 





DHE was utilised as a superoxide anion-specific probe, as previously described [26, 
27]. As shown in Figure 1A, DHE is directly oxidised to ethidium by other ROS, while 
only superoxide anion generates 2OH-Et+. Previous studies described the use of 
liquid chromatography mass spectrometry (LC-MS) to detect 2OH-Et+ in platelets 
[18], which was utilised for the analysis of the redox stress induced by oxidised-LDL 
in platelets. The use of LC-MS requires time-consuming and expensive analyses and 
limits the use of DHE-dependent superoxide anion formation analysis to laboratories 
with access to mass spectrometry facilities. This is a limitation that hinders the 
application of platelet redox analysis using DHE in several academic and clinical 
haematology laboratories. Here, we describe the application of spectral properties 
specific for 2OH-Et+ to the analysis of superoxide anion formation by flow cytometry. 
Only 2OH-Et+ (but not ethidium) has an excitation peak around 400 nm wavelength 
with emission at 580 nm. We took advantage of this property to design a flow 
cytometry assay specifically aimed at detecting 2OH-Et+ and measuring the 
intracellular rate of superoxide anion generation in platelets (Figure 1B).  
As shown in Figure 2, we confirmed the generation of 2OH-Et+ as a product of DHE 
oxidation by superoxide anion in platelets adhering to fibrillar collagen by flow 
cytometry using the spectral properties specific for this chemical species (i.e. 
405/580 nm ex/em). Using single platelet tracking analysis, we could confirm 
superoxide anion generation in platelets upon adhesion and spreading on fibrillar 
collagen. The addition of the ROS scavenger NAC (1 mM) or the NOX inhibitor 
VAS2870 (10 µM) confirmed that the fluorescence measured in this assay is indeed 
due to ROS-dependent DHE oxidation and specifically by NOX activity. 
We then applied the use of DHE to flow cytometry to assess superoxide anion 
generation in platelet suspensions (Figure 3). The spectral properties tested by 
confocal microscopy in Figure 2, were also utilised for the flow cytometry assay (i.e. 
405/580 nm ex/em). The gating utilised to analyse platelet is shown in Figure 3A, 
while an example of 2OH-Et+-specific fluorescence before and after thrombin 
stimulation is shown in Figure 3B. Concentrations of thrombin from 0.1unit/ml (Figure 
3C), CRP from 3µg/ml (Figure 3D) and arachidonic acid from 30 µM (Figure 3E) 
significantly increased fluorescence levels, while ADP did not significantly increase 
2OH-Et+ generation (Figure 3F). In order to confirm that the agonists were able to 
stimulate platelets in the conditions that we chose, platelet aggregation experiments 
were performed, which confirmed all 4 agonists to be active under our experimental 
conditions (Figure 3G).   
In Figure 4A, the concentration-dependent ablation of thrombin-dependent 
superoxide anion formation by NAC is shown, with 3 mM completely inhibiting the 
response. The source of superoxide anion in response to 0.3 units/ml thrombin, 3 
µg/ml CRP and 30 µM arachidonic was then tested using the pan-NOX inhibitor 
VAS2870 [28], which at a concentration of 10 µM is commonly used in vitro to inhibit 
all members of the NOX family [29, 30]. While 3 mM NAC abolished the response 
induced by all three agonists, only thrombin and CRP were inhibited by VAS2870, 
which suggested that these two agonists stimulate superoxide anion generation in a 
NOX-dependent manner (Figure 4B and C, respectively). In contrast, arachidonic 
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acid-induced superoxide anion was not affected by VAS2870 (Figure 4D). 
Interestingly, the cyclooxygenase inhibitor indomethacin inhibited superoxide anion 
formation in response to arachidonic acid, which reflects the dependence of 
arachidonic acid responses on conversion of this agonist into prostaglandin H2 
(PGH2) by cyclooxygenases and the conversion of PGH2 into thromboxane A2 by 
thromboxane synthase [31]. In accordance with these data, thrombin- and CRP-
dependent platelet aggregation was inhibited by 10 µM VAS2870 (Figure 5A-B) and 
3mM NAC (data not shown), while arachidonic acid-dependent aggregation was 
insensitive to VAS2870, but fully inhibited by indomethacin (Figure 5C-D). 3mM NAC 
only partially inhibited arachidonic acid-dependent aggregation (Figure 5C-D), 
despite completely scavenging superoxide anion in response to this agonist (Figure 
4D). 
Finally, we characterised the effect of Aβ peptides on platelet redox homeostasis. In 
our hands, only the long version of the peptide (i.e. Aβ1-42) had a significant effect 
on superoxide generation, while 1-40 and the scrambled peptide used as a control 
had no effect (Figure 6A). A concentration-response study on Aβ 1-42 peptide, 
showed that only medium-to-high micromolar concentrations of this peptide induces 
significant increases in superoxide anion generation (i.e. >10 µM, Figure 6B). As 
seen for thrombin and CRP, both ROS scavenger (NAC and NOX inhibitor VAS2870 
abolished the Aβ1-42 peptide-dependent increase in superoxide anion formation, 
suggesting that NOXs are required for the stimulation of redox stress in human 
platelets in response to Aβ peptide (Figure 6C). We took the opportunity to test the 
ability of Aβ1-42 peptide to induce platelet aggregation. Aβ1-42 induced only 
moderate aggregation at concentration up to 20 µM (Figure 7A). On the other hand, 
the effect of Aβ1-42 peptide on aggregation when co-applied with submaximal 
concentrations of another stimulus was a lot more pronounced. Platelet stimulation 
with 0.03 unit/ml thrombin resulted in negligible aggregation, but in the presence of 5 
and especially 20 µM of Aβ1-42 peptide resulted in a strong aggregation response 
(Figure 7B). Similarly, 10 µM arachidonic acid only induced around 30% aggregation, 
but the aggregation increased to almost 80% in the presence of 20 µM Aβ1-42 
peptide (Figure 7C-D). Interestingly, in the presence of 10 µM VAS2870 Aβ1-42 
peptide did not potentiate arachidonic acid-dependent platelet aggregation, 
suggesting that NOX activity is necessary for the effect of Aβ peptide on human 
platelets. Unfortunately, similar experiments were not possible with thrombin or CRP 
as platelet activation in response to these two stimuli depends on NOX activity and in 
the presence of VAS2870 platelet activation is completely abolished. 
 
Discussion 
The detection of ROS and specifically superoxide anion in platelets is important to 
understand the redox dependence of haemostatic response and its dysregulation in 
thrombotic diseases [32]. Nonetheless, this field of research is suffering from the lack 
of reliable and standardized methodologies for the measurement of intracellular ROS 
in platelets. This makes impossible the comparison of data between studies and 
ultimately slows down the development of this biomedical research area. DCFDA is 
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still widely used in the platelet field despite its relevant limitations due to the 
generation of artefacts and the interaction with pharmacological tools often used for 
cell signalling studies [19, 20]. More reliable methodologies are available but require 
specific skills or equipment that are not readily available in academic and clinical 
laboratories. Amongst these alternatives, electron paramagnetic resonance (EPR) 
spectroscopy is considered the gold standard for the detection of intracellular ROS 
[33]. Unfortunately, in addition to extremely low throughput due to procedural 
complexities and lengthy data analysis, this technique requires highly specialised 
equipment and dedicated personnel, which limit its widespread adoption in research 
and clinical practice. For these reasons the use of redox-sensitive fluoroprobes 
remains attractive, especially if combined with commonly used and relatively 
accessible detection techniques such as cell imaging or flow cytometry. Amongst 
available fluoroprobes, DHE has been described as the most reliable tool for ROS 
detection in live cells [20]. The detection of oxidation products of DHE by liquid 
chromatography mass spectrometry (LC-MS) has been described in several studies, 
including some platelet studies [18], but like EPR spectroscopy it is not readily 
available in most academic and clinical laboratories. Here we describe a 
methodology that combines the reliability of DHE as a redox-sensitive fluoroprobe 
with the advantages of flow cytometry as a detection method (i.e. user-friendliness, 
high throughput and wide adoption in academic research and clinical practice). We 
demonstrated the reliability and usefulness of this technique by performing a detailed 
pharmacological study on the redox properties of physiological platelet agonists 
(including collagen, thrombin, ADP and arachidonic acid) and the pro-thrombotic 
activity of Aβ peptides. 
In this study we confirmed that platelet activation is associated with ROS generation. 
In agreement with previous studies, thrombin [11, 34, 35], collagen (and CRP) [15, 
17] and arachidonic acid [36] were shown to induce superoxide anion generation. 
From these data, it seemed that platelet aggregation and superoxide anion 
generation were intimately associated, but this hypothesis was opposed by our data 
with ADP, which appeared to stimulate platelet aggregation but had no effect on 
platelet superoxide anions. This was somewhat corroborated by literature, in which a 
link between ADP-dependent platelet activation and ROS generation has not been 
convincingly shown. Thanks to the use of a specific NOX inhibitor we could prove 
that NOXs are critical for the oxidative stress induced in platelets by thrombin and 
collagen, which was previously shown [11, 15, 17, 37]. For the first time, we 
demonstrated that the superoxide anion formation induced by arachidonic acid is 
NOX-independent. Aggregation experiments confirmed that arachidonic acid-
induced signalling (which is mediated by conversion of this molecule into 
thromboxane A2 [31]) as well as ADP-mediated platelet activation are independent 
of NOX activity and ROS generation. In these experiments, the ROS scavenger NAC 
only partially inhibited arachidonic acid-dependent aggregation and no effect on 
ADP-dependent aggregation, while NOX inhibitor VAS2870 had no effects on either 
arachidonic- or ADP-dependent platelet aggregation. This suggests the possibility of 
obtaining agonist-specific platelet inhibition of platelets by NOX inhibitors. This was 
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proposed previously [15, 17], although the differential role of NOX1 and NOX2 in 
response to different agonists remains controversial [15, 16, 38]. 
Finally, we utilised the flow cytometry-based detection of superoxide anion formation 
by DHE to clarify the molecular mechanism underlying the pro-thrombotic activity of 
Aβ peptides [21]. We demonstrated a significant association between platelet 
exposure to Aβ peptides and oxidative stress, which has been described [39]. 
Importantly, in this study we identified superoxide anions as the ROS induced by Aβ 
peptides and, more importantly, we show that NOXs are crucial for oxidative stress 
and platelet aggregation potentiation induced by Aβ peptides. This is an interesting 
finding suggesting NOX as potential therapeutic targets to address the pro-
thrombotic activity of Aβ peptide [40] and treat neurovascular ischemia associated 
with Alzheimer’s disease [41, 42]. Although recent studies focussed on different Aβ 
peptides for their effects on platelet function (e.g. Aβ 25-35 [22], Aβ 1-40 [21]), only 
Aβ peptide 1-42 appeared to significantly stimulate superoxide anion formation. This 
is an extremely interesting observation as it may suggest specific binding modalities 
for the more hydrophobic Aβ peptide 1-42 compared to Aβ peptide 1-40.  
In summary, here we describe a novel, reliable and easily accessible methodology 
for the measurement of superoxide anion formation in platelets. Its application in our 
study led to interesting observations on the redox properties of physiological platelet 
agonists and Aβ peptides, which highlights how useful this assay can be in the study 
of haemostasis and thrombosis. 
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